Therapeutic potential of clinical-grade ACE2 for blocking SARS-CoV-2 variants

According to new research by an international team of scientists, all SARS-CoV-2 variants, including variants of concern (VOC) Alpha, Beta, Gamma, and Delta, exhibit enhanced affinity toward recombinant human soluble ACE2.

Generated by Feedzy